Cargando…
Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics
Though aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules in biological samples enabling detailed mapping of pathways involved in drug response. We defined the metabolic s...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001726/ https://www.ncbi.nlm.nih.gov/pubmed/23839601 http://dx.doi.org/10.1038/clpt.2013.119 |
_version_ | 1782313752244256768 |
---|---|
author | Yerges-Armstrong, Laura M. Ellero-Simatos, Sandrine Georgiades, Anastasia Zhu, Hongjie Lewis, Joshua Horenstein, Richard B. Beitelshees, Amber L. Dane, Adrie Reijmers, Theo Hankemeier, Thomas Fiehn, Oliver Shuldiner, Alan R. Kaddurah-Daouk, Rima |
author_facet | Yerges-Armstrong, Laura M. Ellero-Simatos, Sandrine Georgiades, Anastasia Zhu, Hongjie Lewis, Joshua Horenstein, Richard B. Beitelshees, Amber L. Dane, Adrie Reijmers, Theo Hankemeier, Thomas Fiehn, Oliver Shuldiner, Alan R. Kaddurah-Daouk, Rima |
author_sort | Yerges-Armstrong, Laura M. |
collection | PubMed |
description | Though aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules in biological samples enabling detailed mapping of pathways involved in drug response. We defined the metabolic signature of aspirin exposure in subjects from the Heredity and Phenotype Intervention (HAPI) Heart Study. Many metabolites, including known aspirin catabolites, changed upon exposure to aspirin and pathway enrichment analysis identified purine metabolism as significantly affected by drug exposure. Further, purines were associated with aspirin response and poor responders had higher post-aspirin adenosine and inosine than good responders (N=76;p<4×10(-3) both). Using our established “pharmacometabolomics-informs-pharmacogenomics” approach we identified genetic variants in adenosine kinase (ADK) associated with aspirin response. Combining metabolomics and genomics allowed for more comprehensive interrogation of mechanisms of variation in aspirin response - an important step toward personalized treatment approaches for cardiovascular disease. |
format | Online Article Text |
id | pubmed-4001726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
record_format | MEDLINE/PubMed |
spelling | pubmed-40017262014-10-01 Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics Yerges-Armstrong, Laura M. Ellero-Simatos, Sandrine Georgiades, Anastasia Zhu, Hongjie Lewis, Joshua Horenstein, Richard B. Beitelshees, Amber L. Dane, Adrie Reijmers, Theo Hankemeier, Thomas Fiehn, Oliver Shuldiner, Alan R. Kaddurah-Daouk, Rima Clin Pharmacol Ther Article Though aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules in biological samples enabling detailed mapping of pathways involved in drug response. We defined the metabolic signature of aspirin exposure in subjects from the Heredity and Phenotype Intervention (HAPI) Heart Study. Many metabolites, including known aspirin catabolites, changed upon exposure to aspirin and pathway enrichment analysis identified purine metabolism as significantly affected by drug exposure. Further, purines were associated with aspirin response and poor responders had higher post-aspirin adenosine and inosine than good responders (N=76;p<4×10(-3) both). Using our established “pharmacometabolomics-informs-pharmacogenomics” approach we identified genetic variants in adenosine kinase (ADK) associated with aspirin response. Combining metabolomics and genomics allowed for more comprehensive interrogation of mechanisms of variation in aspirin response - an important step toward personalized treatment approaches for cardiovascular disease. 2013-06-11 2013-10 /pmc/articles/PMC4001726/ /pubmed/23839601 http://dx.doi.org/10.1038/clpt.2013.119 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Yerges-Armstrong, Laura M. Ellero-Simatos, Sandrine Georgiades, Anastasia Zhu, Hongjie Lewis, Joshua Horenstein, Richard B. Beitelshees, Amber L. Dane, Adrie Reijmers, Theo Hankemeier, Thomas Fiehn, Oliver Shuldiner, Alan R. Kaddurah-Daouk, Rima Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title | Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title_full | Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title_fullStr | Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title_full_unstemmed | Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title_short | Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics |
title_sort | purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed-pharmacogenomics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001726/ https://www.ncbi.nlm.nih.gov/pubmed/23839601 http://dx.doi.org/10.1038/clpt.2013.119 |
work_keys_str_mv | AT yergesarmstronglauram purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT ellerosimatossandrine purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT georgiadesanastasia purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT zhuhongjie purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT lewisjoshua purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT horensteinrichardb purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT beitelsheesamberl purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT daneadrie purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT reijmerstheo purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT hankemeierthomas purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT fiehnoliver purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT shuldineralanr purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT kaddurahdaoukrima purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics AT purinepathwayimplicatedinmechanismofresistancetoaspirintherapypharmacometabolomicsinformedpharmacogenomics |